These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38735753)

  • 1. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
    Wang Y; Geldres C; Ferrone S; Dotti G
    Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
    Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
    J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
    Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
    Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
    Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
    J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSPG4 in cancer: multiple roles.
    Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
    Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
    Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
    Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
    Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
    Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 12. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.
    Fenton M; Whiteside TL; Ferrone S; Boyiadzis M
    Oncol Res; 2015; 22(2):117-21. PubMed ID: 25706398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
    Campoli M; Ferrone S; Wang X
    Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen.
    Nounamo B; Jousheghany F; Siegel ER; Post SR; Kelly T; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.
    Chen X; Habib S; Alexandru M; Chauhan J; Evan T; Troka JM; Rahimi A; Esapa B; Tull TJ; Ng WZ; Fitzpatrick A; Wu Y; Geh JLC; Lloyd-Hughes H; Palhares LCGF; Adams R; Bax HJ; Whittaker S; Jacków-Malinowska J; Karagiannis SN
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
    Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
    Front Oncol; 2022; 12():939166. PubMed ID: 36110930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
    Harrer DC; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.
    Yu X; Qu L; Bigner DD; Chandramohan V
    Protein Eng Des Sel; 2017 Sep; 30(9):639-647. PubMed ID: 28981720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
    Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
    Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.